A
ARCT
Arcturus Therape
8.03
+0.18+2.29%After Hours: 7.88 -0.15 -1.87%19:44 04/02 EDT
OPEN/PREV CLOSE7.52/7.85
TODAY RANGE7.52-8.27
VOL506.12K
MARKET CAP228.24M
52 WEEK RANGE5.85-24.17
AVG VOL (3M)508.63K
% TURNOVER1.78%
TURNOVER--
P/E (TTM)-3.3429
% RANGE9.53%
EPS(TTM)-2.4021
P/E(FORWARD)-1.9051
P/B1.066
BVPS7.53
DIVIDEND--
P/S2.781
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP211.06M
SHARES OUTSTANDING28.42M
NEXT EARNINGS05/11-05/15
FREE FLOAT26.28M
LOT SIZE1
EX-DATE11/16/2017
News
Press Releases
Financial Reports
Profile
Seeking Alpha·4d ago
Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names
TipRanks·03/26 22:55
Roth MKM Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Benzinga·03/20 13:01
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Benzinga·03/20 11:48
This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday
Benzinga·03/19 13:26
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Benzinga·03/19 13:14
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga·03/19 13:05
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday
Benzinga·03/18 12:00
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Dow Jones·03/18 10:56
Arcturus Therapeutics Price Target Announced at $22.00/Share by B. Riley Securities
TipRanks·03/18 09:05
Arcturus Therapeutics initiated with a Buy at B. Riley
Reuters·03/18 07:36
U.S. RESEARCH ROUNDUP-Factset, Lensar, Starbucks
Seeking Alpha·03/06 21:04
Arcturus Therapeutics: Downgrading To "Hold" As CF Program Shifts Population Focus
Benzinga·03/05 22:01
Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.